INVESTORS

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Enumeral and ICAV to Pursue Infectious Disease Collaboration

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 5, 2017-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and advancement of next generation therapeutics in cancer and other diseases, today announced that Enumeral and the International Consortium on Anti-Virals (“ICAV”) have entered into a memorandum of understanding to pursue an infectious disease collaboration utilizing Enumeral's proprietary platform. The goal of the collaboration is to isolate and characterize high affinity, broadly neutralizing human antibodies against select human pathogens from patients previously infected or vaccinated for therapeutic intervention, prophylaxis, and/or diagnostic utility.

Under this collaboration, ICAV would provide patient samples, reagents for target screening from their worldwide collaborator network, and critical functional screening. Enumeral will use its proprietary platform to identify high affinity antibodies and provide sufficient quantities for testing and candidate selection. Each party would bear its own costs and expenses in the study. Enumeral and ICAV anticipate that upon completion of the initial collaboration phase, the parties would seek to secure funding from various governments, international agencies, and foundations to pursue additional targets. The memorandum of understanding is non-binding, and Enumeral and ICAV will endeavor to negotiate final collaboration agreements that will set forth the terms and conditions of the proposed study in greater detail.

“Identifying therapeutic human antibodies is an excellent application of our technology platform to discover potential next-generation therapeutics while significantly reducing development timelines and costs,” said Wael Fayad, Chairman, President and Chief Executive Officer of Enumeral. “We believe this collaboration study will further validate our technology platform and demonstrate its potential value, not only in infectious disease but also in other therapeutic areas. ICAV is a leader in developing therapies that could serve as the first line of defense in the next pandemic situation, and we are excited to be collaborating with them.”

“Rapidity of response is the key to containing infectious disease outbreaks and thus preventing them from becoming epidemics or pandemics. This collaboration will evaluate the contribution that Enumeral’s platform could make to significantly shorten the time taken to intervene in the next infectious disease outbreak with pandemic potential,” said Dr. Jeremy Carver, President and Chief Executive Officer of the International Consortium on Anti-Virals.

About Enumeral

Enumeral is a biopharmaceutical company focused on the discovery and advancement of next generation therapeutics in cancer, auto-immune, and other diseases. The Company utilizes a proprietary microwell array technology to identify cell type and measure functioning of individual cells from tissue samples, and to retrieve individual live cells of interest, for cell culture or gene cloning. This technology provides key insights for target validation, drug candidate selection, and rational drug development. The company has built a pipeline of immune checkpoint modulators for targets including PD-1, TIM-3, CD39, and others. For more information on Enumeral, please visit www.enumeral.com.

About ICAV

The International Consortium on Anti-Virals (ICAV)/Consortium International sur les Thérapies Antivirales (CITAV) is a Canadian “not-for-profit” drug development company founded in 2004 to discover and develop novel anti-viral therapies for neglected and emerging diseases, and to ensure their global accessibility to all those in need. ICAV recognizes the need for the international community to establish a capability to detect, contain and treat diseases and pandemics promptly in both the developed and developing worlds. ICAV supports the development of therapies for such viruses as Influenza, Dengue, HIV, Hepatitis, Lassa, Yellow Fever, Chikungunya, Ebola and Marburg, and other infectious diseases. For more information on ICAV, please visit www.icav-citav.ca.

Forward Looking Statements Disclosure

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements reflect current beliefs of Enumeral Biomedical Holdings, Inc. (“Enumeral” or the “Company”) with respect to future events and involve known and unknown risks, uncertainties, and other factors affecting operations, market growth, Enumeral’s stock price, services, products and licenses. No assurances can be given regarding the achievement of future results, and although Enumeral believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, actual results may differ from the assumptions underlying the statements that have been made regarding anticipated events. Factors that may cause actual results, performance or achievements, or industry results to differ materially from those contemplated by such forward-looking statements may include, without limitation, (a) Enumeral’s ability to raise capital when needed and on acceptable terms and conditions, cash flows and resulting liquidity, (b) Enumeral’s expectations regarding market acceptance of the Company’s business in general and the Company’s ability to penetrate the antibody discovery and development fields in particular, as well as the timing of such acceptance, (c) Enumeral’s ability to attract and retain management with experience in biotechnology and antibody discovery and similar emerging technologies, (d) Enumeral’s ability to partner with other companies to bring product candidates through the development stage and eventually to market, (e) the scope, validity and enforceability of Enumeral’s and third party intellectual property rights, (f) Enumeral’s ability to comply with governmental regulation, (g) the intensity of competition, (h) changes in the political and regulatory environment and in business and fiscal conditions in the United States and overseas, and (i) general economic conditions.

More detailed information about Enumeral and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in Enumeral’s filings with the Securities and Exchange Commission. Enumeral urges investors and security holders to read those documents free of charge at the Commission’s website at http://www.sec.gov. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, Enumeral undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

Source: Enumeral Biomedical Holdings, Inc.

Enumeral Biomedical Holdings, Inc.
Kevin Sarney, 617-945-9146
kevin@enumeral.com
or
ICAV/CITAV
Dale Cumming, Ph.D., 978-219-9320
dale.cumming@icav-usa.org